These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 17963025)

  • 1. Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat.
    Peters SA; Hultin L
    J Pharmacokinet Pharmacodyn; 2008 Feb; 35(1):1-30. PubMed ID: 17963025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):261-75. PubMed ID: 18336055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Physiologically Based Pharmacokinetic Models to Predict the Absorption of BCS Class I Drugs in Different Pediatric Age Groups.
    Liu XI; van den Anker JN; Burckart GJ; Dallmann A
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S94-S107. PubMed ID: 34185902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appearance of double peaks in plasma concentration-time profile after oral administration depends on gastric emptying profile and weight function.
    Metsugi Y; Miyaji Y; Ogawara K; Higaki K; Kimura T
    Pharm Res; 2008 Apr; 25(4):886-95. PubMed ID: 17955185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable gastric emptying and discontinuities in drug absorption profiles: dependence of rates and extent of cimetidine absorption on motility phase and pH.
    Langguth P; Lee KM; Spahn-Langguth H; Amidon GL
    Biopharm Drug Dispos; 1994 Dec; 15(9):719-46. PubMed ID: 7888602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethanol-drug absorption interaction: potential for a significant effect on the plasma pharmacokinetics of ethanol vulnerable formulations.
    Lennernäs H
    Mol Pharm; 2009; 6(5):1429-40. PubMed ID: 19655809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using Physiologically Based Pharmacokinetic (PBPK) Modelling to Gain Insights into the Effect of Physiological Factors on Oral Absorption in Paediatric Populations.
    Villiger A; Stillhart C; Parrott N; Kuentz M
    AAPS J; 2016 Jul; 18(4):933-47. PubMed ID: 27060007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling and PBPK simulation in drug discovery.
    Jones HM; Gardner IB; Watson KJ
    AAPS J; 2009 Mar; 11(1):155-66. PubMed ID: 19280352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Physiologically Based Pharmacokinetic Modeling for Predicting Drug-Food Interactions: Recommendations for Improving Predictive Performance of Low Confidence Food Effect Models.
    Wagner C; Kesisoglou F; Pepin XJH; Parrott N; Emami Riedmaier A
    AAPS J; 2021 Jun; 23(4):85. PubMed ID: 34142242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of paracetamol in Göttingen minipigs: in vivo studies and modeling to elucidate physiological determinants of absorption.
    Suenderhauf C; Tuffin G; Lorentsen H; Grimm HP; Flament C; Parrott N
    Pharm Res; 2014 Oct; 31(10):2696-707. PubMed ID: 24792825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
    Kortejärvi H; Urtti A; Yliperttula M
    Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the whole body physiologically based pharmacokinetic (WB-PBPK) modeling of drugs.
    Munir A; Azam S; Fazal S; Bhatti AI
    J Theor Biol; 2018 Aug; 451():1-9. PubMed ID: 29704489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A physiologically-based drug absorption modeling for orally disintegrating tablets.
    Kambayashi A; Kiyota T
    Eur J Pharm Biopharm; 2020 Jul; 152():1-9. PubMed ID: 32371153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling.
    Jones HM; Gardner IB; Collard WT; Stanley PJ; Oxley P; Hosea NA; Plowchalk D; Gernhardt S; Lin J; Dickins M; Rahavendran SR; Jones BC; Watson KJ; Pertinez H; Kumar V; Cole S
    Clin Pharmacokinet; 2011 May; 50(5):331-47. PubMed ID: 21456633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
    Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
    Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
    Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically Based Pharmacokinetic Models Can Be Used to Predict the Unique Nonlinear Absorption Profiles of Vismodegib.
    Lin L; Wright MR; Hop CECA; Wong H
    Drug Metab Dispos; 2022 Sep; 50(9):1170-1181. PubMed ID: 35779865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.